Entering text into the input field will update the search result below

Biocept GAAP EPS of -$1.89 misses by $0.84, revenue of $25.9M beats by $18.65M

Apr. 18, 2023 2:33 AM ETBiocept, Inc. (BIOCQ)By: Meghavi Singh, SA News Editor1 Comment
  • Biocept press release (NASDAQ:BIOC): FY GAAP EPS of -$1.89 misses by $0.84.
  • Revenue of $25.9M (-57.6% Y/Y) beats by $18.65M.
  • Biocept reported cash of $12.9 million as of December 31, 2022, compared with $28.9 million as of December 31, 2021.
  • The number of commercial accessions delivered for 2022 and 2021 were 294,182 and 532,520, respectively.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

bluescorpion0 profile picture
can anyone tell me if their cnside cancer assay is based on gene sequencing or something unique? Who else is doing this blood biomarket type test? Also does it help with outcomes for patients? Thanks.


SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Biocept, Inc.
ContraFect Corporation
SQZ Biotechnologies Company
Athersys, Inc.
Kintara Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.